An observational study in Colorectal Carcinoma, sponsored by Sohag University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by Sohag University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Colorectal Neoplasms with a site in Egypt — 15 open to participants now, 17 under way, 5 of them phase 3. Colorectal Neoplasms · Egypt.
Among the 55 studies in Colorectal Neoplasms with a site in Egypt, this one is the 20th largest by planned enrollment of the 23 observational ones that give a count, is one of 5 that started in 2025, is one of 23 observational ones, reaches primary completion later than 7 of the 16 other live ones, and was the 44th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →15 of the 55 studies in Colorectal Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 18+
Ahmed Adel Ahmed Elsayed Ali Radwan · Sites in Egypt
Ages 40–59
Minia University · Sites in Egypt
Ages 18–80
Sohag University · Sites in Egypt
Ages 18–80
toqa saad mohammed mohammed · Sites in Egypt
Ages 18+ · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 13 · Phase 4 1
First in 1999; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 60 across the 31 interventional studies, 96 across the 23 observational. Of the 29 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 55 have an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Sohag University has 9 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Colorectal Neoplasms with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07736495Phase 3Ain Shams UniversityProtective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis | 2026-12-27 |
| NCT07922642Alexandria UniversityNurse-Led Prehabilitation Before Major Abdominal Cancer Surgery | 2027-02-05 |
| NCT07144683Minia UniversityAnastomotic Leakage After Colorectal Surgery. | 2027-03-25 |
| NCT07874035Ahmed Adel Ahmed Elsayed Ali RadwanLow Load Blood Flow Restriction Resistance Training in Colorectal Cancer Related Sarcopenia | 2027-08-15 |
| NCT07215936Sohag UniversityDose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 55 studies in Colorectal Neoplasms with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluation of the immunohistochemical expression of p16 in colorectal carcinoma and correlate its expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.
Colorectal Carcinoma is very common nowadays, with increasing need for further research.
p16 is tumor suppressor gene with a vital rule ; inactivation of p16 leads to tumor formation and progression.
50 Specimens will be collected from Pathology Department of Sohag University Hospital. Sufficient clinical and histopathological data will be attached for each case.
The previously processed formalin-fixed, paraffin-embedded tissue blocks will be used to get Hematoxylin \& Eosin stained sections to confirm the diagnosis and to detect the histopathological type, grade and stage of each tumor.
Another sliced tissue sections will be immunohistochemically stained with p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.
Fifty (50) cases of colorectal cancer will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Fifty (50) cases of colorectal cancer will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.
Biological: Immunohistochemical staining
Immunohistochemical staining of paraffin embedded blocks of colorectal carcinoma tissues by p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.
Evaluation of p16 Expression in Colorectal Carcinoma.
Immunohistochemical staining of Colorectal tissues by p16 monoclonal antibody
Time frame: 6 months
Correlation of p16 expression to different clinical and pathological parameters
Correlation of p16 expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.
Time frame: 6 months
Plan to share: Undecided — Not decided yet
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Mar 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.